PD-L1-positive recurrent and metastatic cervical cancer responsive to first-line Sintilimab with chemotherapy plus Bevacizumab treatment: a case report
preprint
OA: closed
Abstract
Cervical cancer is the most common malignant tumor of the female reproductive system. Its incidence rate ranks first among that of female malignant tumors in China and has steadily increased in recent years [Juanjuan Jin et al., 2021].
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00
- unpaywall
- last seen: 2026-09-07T06:27:18.705824+00:00